...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of population therapeutics and clinical pharmacology >Cutaneous adverse drug reactions in children: An analysis of reports from the Canadian Pharmacogenomics Network for drug safety (CPNDS)
【24h】

Cutaneous adverse drug reactions in children: An analysis of reports from the Canadian Pharmacogenomics Network for drug safety (CPNDS)

机译：儿童的皮肤药物不良反应：加拿大药物基因组网络药物安全性（CPNDS）的报告分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cutaneous adverse drug reactions (CADRs) are the most prevalent adverse drug reactions (ADRs) in hospitalized children, with an estimated rate of 2-3%. The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) is a pan-Canadian active surveillance network identifying genomic biomarkers of risk for serious ADRs. The purpose of this paper is to describe the characteristics of paediatric CADR cases reported to the CPNDS from February 2005 to December 2008. The CPNDS database was mined and details of CADRs and key clinical data from cases were extracted. Reports were individually analyzed and classified in two main groups: severe and non-severe CADRs, with subcategories. In total, 326 CADR cases were included in the study; 214 (65.6%) severe and 112 (34.4%) non-severe CADRs. Overall L-asparaginase (n=56, 16%), amoxicillin (n=29, 8.3%), cotrimoxazole (n=25, 7.2%), carbamazepine (n=17, 4.9%) and lamotrigine (n=13, 3.7%) accounted for 40% of all suspected medications. We have demonstrated the ability to comprehensively collect clinical data on a wide range of severe and non-severe CADRs to drugs commonly used in the care of children. Our study provides additional real world evidence to promote the proactive detection, collection, reporting and assessment of CADRs in children.
机译：皮肤药物不良反应（CADR）是住院儿童中最普遍的药物不良反应（ADR），估计发生率为2-3％。加拿大药物基因组学药物安全网络（CPNDS）是一个泛加拿大的主动监视网络，用于识别严重ADR风险的基因组生物标志物。本文旨在描述2005年2月至2008年12月报告给CPNDS的小儿CADR病例的特征。挖掘CPNDS数据库并提取CADR的详细信息和病例的关键临床数据。对报告进行了单独分析并将其分为两个主要类别：严重和非严重CADR，以及子类别。总共326例CADR病例被纳入研究。 214（65.6％）个严重和112（34.4％）个非严重CADR。总体L-天冬酰胺酶（n = 56，16％），阿莫西林（n = 29，8.3％），卡曲咪唑（n = 25，7.2％），卡马西平（n = 17，4.9％）和拉莫三嗪（n = 13，3.7 ％）占所有可疑药物的40％。我们已经证明了能够广泛收集各种重度和非重度CADR的临床数据，以及针对儿童护理常用药物的临床数据。我们的研究提供了其他现实世界的证据，以促进对儿童CADR的主动检测，收集，报告和评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号